Maintaining appropriate anticoagulation with vitamin K antagonists (eg phenprocoumon) is challenging due to their regular monitoring of INR in blood sample and the consecutive dose adaptation with split tablets. Switching these patients to NOACs (new oral anticoagulants, eg rivaroxavan) has been advocated to facilitate treatment and thus ameliorate outcome because of the lack of monitoring and a plain tablet to take once or twice daily. Little is known about patients preferences when they are faced to different anticoagulation therapy in prevention of severe and potential fatal diseases (atrial fibrillation, pulmonary embolism, hip or knee replacement surgery, deep vein thrombosis) and when monitoring is possible or not. In this context, we will develop questions of interest for the Pharmaceutical care counseling of patients with anticoagulation.